California 2021-2022 Regular Session

California Assembly Bill AB752

Introduced
2/16/21  
Refer
2/25/21  
Refer
2/25/21  
Report Pass
3/18/21  
Report Pass
3/18/21  
Refer
3/22/21  
Refer
3/22/21  
Report Pass
3/30/21  
Report Pass
3/30/21  
Refer
4/5/21  
Refer
4/5/21  
Report Pass
4/14/21  
Report Pass
4/14/21  
Refer
4/19/21  
Refer
4/19/21  
Refer
5/5/21  
Failed
2/1/22  

Caption

Prescription drug coverage.

Impact

The implementation of AB 752 will impact the manner in which health care service plans and insurers operate concerning prescription drug coverage. It requires them to respond in real-time to any inquiries about covered drugs, detailing eligibility and cost-sharing agreements. By doing so, the legislation aims to help patients make informed decisions regarding their prescriptions, potentially leading to better health outcomes and enhanced satisfaction with health care services. Moreover, it is designed to curb practices that may restrict providers from sharing necessary information with patients.

Summary

Assembly Bill 752, introduced by Assembly Member Nazarian, addresses prescription drug coverage within the state of California. This legislation aims to enhance transparency and accessibility of prescription drug information for both enrollees and their healthcare providers. Specifically, it mandates health care service plans and insurers to provide comprehensive information regarding drug eligibility, formulary lists, and cost-sharing details upon request. The bill is a step toward improving communication between patients, providers, and insurers, ensuring that critical information regarding prescriptions is readily available without unnecessary hurdles.

Sentiment

The sentiment regarding AB 752 appears largely supportive among health care advocates, who argue that improved access to prescription information is vital for patient care. Advocates assert that transparency in drug costs and coverage will empower patients to seek more affordable alternatives, thus making healthcare more accessible. However, there may be some concern from insurers regarding the operational implications of the bill, particularly the requirement for real-time responses, which they fear could burden their existing systems.

Contention

While AB 752 has garnered support for enhancing drug coverage transparency, there are contentions surrounding the bill's requirements that may impose additional administrative responsibilities on health insurers and service plans. Critics express concern over potential cost implications and the operational feasibility of ensuring compliance with the real-time response mandate and sharing of comprehensive cost-sharing information with enrollees and providers. These discussions highlighted the balance between improving patient access to information and the administrative burden placed on insurers.

Companion Bills

No companion bills found.

Previously Filed As

CA SB70

Prescription drug coverage.

CA AB948

Prescription drugs.

CA SB621

Health care coverage: biosimilar drugs.

CA SB873

Prescription drugs: cost sharing.

CA AB2169

Prescription drug coverage: dose adjustments.

CA SB786

Prescription drug pricing.

CA SB427

Health care coverage: antiretroviral drugs, drug devices, and drug products.

CA AB2180

Health care coverage: cost sharing.

CA AB1060

Health care coverage: naloxone hydrochloride.

CA SB516

Health care coverage: prior authorization.

Similar Bills

CA AB2352

Prescription drug coverage.

CA SB854

Health care coverage: substance use disorders.

CA AB1011

Health care coverage: substance use disorders.

MA H4411

Relating to patient cost, benefit and coverage information, choice, and price transparency

MA S2637

Relating to patient cost, benefit and coverage information, choice, and price transparency

MA S616

Relating to patient cost, benefit and coverage information, choice, and price transparency

CA AB2384

Medication-assisted treatment.

MA H1131

Relating to patient cost, benefit and coverage information, choice, and price transparency